AeroLeads people directory · profile
Wian De Jongh Email & Phone Number
CEO
at
AdaptVac
1 work email found
@expres2ionbio.com
LinkedIn matched
✓ Verified August 2026
4 data sources
Profile completeness 100%
Current company
Role
CEO
Location
Copenhagen, Capital Region of Denmark, Denmark
Company size
Who is Wian De Jongh? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Wian De Jongh is listed as CEO at AdaptVac, a with 11 employees, based in Copenhagen, Capital Region of Denmark, Denmark. AeroLeads shows a work email signal at expres2ionbio.com and a matched LinkedIn profile for Wian De Jongh.
Wian De Jongh previously worked as Board Member at Glyprovac Llc and Affiliated Associate Professor at Dtu - Technical University Of Denmark. Wian De Jongh holds Ph.D, Biotechnology from Dtu - Technical University Of Denmark.
Company email context
Email format at AdaptVac
This section adds company-level context without repeating Wian De Jongh's masked contact details.
*@expres2ionbio.com
68% confidence
AeroLeads found 1 current-domain work email signal for Wian De Jongh. Compare company email patterns before reaching out.
Profile bio
About Wian De Jongh
Dr. de Jongh is CEO and Co-founder of AdaptVac since 2017, which has Virus-Like Particle (VLP) vaccine development projects against COVID-19 (out-licensed to Bavarian Nordic), Placental Malaria, Nipah and Filo viruses, as well as a vaccine against Her2+ breast cancer out-licensed to ExpreS2ion Biotechnologies. He further has >14 years C-level experience including as CSO and Co-founder of NASDAQ First North listed ExpreS2ion Biotechnologies. During this time he was involved in a range of research projects with partners, specifically in screening a large number of possible vaccine candidates and in developing a placental malaria vaccine production process in collaboration with the Center for Medical Parasitology in Copenhagen University. Furthermore, Dr. de Jongh managed the upstream process development and CMC transfer activities for a second blood stage malaria vaccine in collaboration with The Jenner Institute, Oxford University. The placental malaria project completed PhIa trials in Germany, and PhIb trial in Benin. The Jenner Institute has successfully developed the Rh5 malaria blood stage vaccine to a successful PhII study in Tanzania (2024), with further studies planned.KEY STRENGTHS• Scientific strategy• Insect cell line development for clinical use• Process development• CMC project transfer• Regulatory meetings• B2B relationship management• Project/Program management• Establishment of strategic collaborations • Grant funding application and management• Commercialization of high-tech products
Listed skills include Molecular Biology, Vaccines, Protein Expression, High Throughput Screening, and 12 others.
Current workplace
Wian De Jongh's current company
Company context helps verify the profile and gives searchers a useful next step.
Adaptvac
12 roles
Wian De Jongh work experience
A career timeline built from the work history available for this profile.
Board Member
Current
Jul 2021 - Present
Ceo
CurrentAdaptVac's current focus is the development of a Nipah virus vaccine based on our capsid Virus-Like Particle (cVLP) technology platform. AdaptVac's COVID-19 vaccine was licensed by Bavarian Nordic, and our HER2+ cancer cVLP based vaccine was licensed by ExpreS2ion Biotechnologies for further clinical development.
Oct 2017 - Present
Affiliated Associate Professor
CurrentORCID ID: https://orcid.org/0000-0001-7983-956X
Feb 2017 - Present
Cso
MANAGEMENT ROLES• Responsibility for scientific strategy, collaborations, Quality Assurance (QA), Regulatory Affairs (RA), and day-to-day running of the lab.• Managing establishment of cGMP compatible monoclonal RCB’s (Research cell banks) and setup of the quality system to which this work is done. • Project manager overseeing internal process development and transfer to CMOs for cGMP manufacture.REGULATORY EXPERIENCEPresented cell line development and Master Cell bank (MCB) viral safety testing, as well as the production process development and viral clearance study for the Placental Vaccine Malaria project with Copenhagen University in regulatory meetings with:• PEI, Germany (2014)• MPA, Sweden (2013)Presented the cell line development and viral safety testing, as well as the upstream production process development and viral clearance study for the Rh5 Malaria vaccine project with The Jenner Institute, Oxford University in regulatory meetings with:• MHRA, Britain (2014)
Jun 2012 - Dec 2020
Co-Founder
ExpreS2ion Bio offers services related to vector development, cell line development, cloning, upstream development and optimization, and production of GLP material. The company is based on proprietary Drosophila S2 insect cell technology that was developed over ten years at Pharmexa/Affitech by the founders of ExpreS2ion Bio and their team.
Jan 2010 - Dec 2020
Vp, Product Development
Mar 2011 - May 2012
Scientist, Team Leader Insect Cell Expression
Development of high-throughput insect cell expression systems for the expression of human desease related proteins.
Feb 2010 - Feb 2011
Research Scientist
Responsible molecular biologist for expression vector development of a novel insect cell expression system. Further cell line and fermentation process development of an insect cell expression system.Molecular biology laboratory manager
Jun 2008 - Feb 2010
Protein Expression Scientist
Upstream process development of insect cell produced protein based vaccines. Successful upstream process transfer for clinical trial material manufacture at a British contract manufacturer (2007). Responsible scientist for prokaryotic protein expression projects.Technology project manager: Evaluation and in-licensing of new prokaryotic expression systems (2006-2008)
Jan 2006 - May 2008
Research Assistant
This work resulted in a paper: De Jongh, et al. 2008 “The role of gal1-P, galactitol and phosphoglucomutase in galactose induced toxicity in S. cerevisiae”. Biotechnol Bioeng
Oct 2001 - Sep 2002
Junior Consultant
Irsot, Dept. Of Chemical Engineering, University Of Stellenbosch
Junior member of a three person team consulting on process and emission issues
Mar 2001 - Sep 2001
Team & coworkers
Colleagues at AdaptVac
Other employees you can reach at adaptvac.com. View company contacts for 11 employees →
3 education records
Wian De Jongh education
Ph.D, Biotechnology
Dtu - Technical University Of Denmark
Masters, Chemical Engineering
Stellenbosch University
B. Eng, Chemical Engineering
Stellenbosch University
FAQ
Frequently asked questions about Wian De Jongh
Quick answers generated from the profile data available on this page.
What company does Wian De Jongh work for?
Wian De Jongh works for AdaptVac.
What is Wian De Jongh's role at AdaptVac?
Wian De Jongh is listed as CEO at AdaptVac.
What is Wian De Jongh's email address?
AeroLeads has found 1 work email signal at @expres2ionbio.com for Wian De Jongh at AdaptVac.
Where is Wian De Jongh based?
Wian De Jongh is based in Copenhagen, Capital Region of Denmark, Denmark while working with AdaptVac.
What companies has Wian De Jongh worked for?
Wian De Jongh has worked for Adaptvac, Glyprovac Llc, Dtu - Technical University Of Denmark, Expres2Ion Biotechnologies, and The Novo Nordisk Foundation Center For Protein Research.
Who are Wian De Jongh's colleagues at AdaptVac?
Wian De Jongh's colleagues at AdaptVac include Sanna Hentze Vestergaard, Cyrielle Fougeroux, and Louise Goksøyr.
How can I contact Wian De Jongh?
You can use AeroLeads to view verified contact signals for Wian De Jongh at AdaptVac, including work email, phone, and LinkedIn data when available.
What schools did Wian De Jongh attend?
Wian De Jongh holds Ph.D, Biotechnology from Dtu - Technical University Of Denmark.
What skills is Wian De Jongh known for?
Wian De Jongh is listed with skills including Molecular Biology, Vaccines, Protein Expression, High Throughput Screening, Glp, Lifesciences, Biotechnology, and Cell Culture.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial